IGM Biosciences Inc Stock

$1.12

3.70% yesterday

Nasdaq, Jun 30, 10:00 pm CET

ISIN

US4495851085

Symbol

IGMS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

IGM Biosciences Inc Stock price

$1.12

-71.88 98.47% 5Y

Nasdaq, Closing price Mon, Jun 30 2025

+0.04 3.70%

ISIN

US4495851085

Symbol

IGMS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$64.9m

Enterprise Value

$-87.2m

Net debt

positive

Cash

$152.1m

Shares outstanding

60.1m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

24.23 | 10.34

EV/Sales

negative | negative

EV/FCF

0.60

P/B

93.10

Financial Health

Equity Ratio

18.13%

Return on Equity

-406.45%

ROCE

-96.01%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$2.7m | $6.3m

EBITDA

$-162.3m | $-86.2m

EBIT

$-171.6m

Net Income

$-198.9m | $-65.1m

Free Cash Flow

$-146.5m

Growth (TTM | estimate)

Revenue

27.01% | 134.22%

EBITDA

33.78% | 53.43%

EBIT

32.45%

Net Income

16.06% | 66.75%

Free Cash Flow

24.71%

Margin (TTM | estimate)

Gross

EBITDA

-6,055.35% | -1,373.43%

EBIT

-6,398.81%

Net

-7,417.79% | -1,037.06%

Free Cash Flow

-5,464.27%

EPS

$-3.25

FCF per Share

$-2.44

Short interest

3.68%

Employees

149.00

Rev per Employee

$20.00k

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Get Started for Free Today

IGM Biosciences Inc Stock Analysis

Unlock Scores for Free

??

10 Analysts have issued a IGM Biosciences Inc forecast:

6x Hold

60%

4x Sell

40%

More details on Analyst Estimates Including Price Targets

10 Analysts have issued a IGM Biosciences Inc forecast:

Hold

60%

Sell

40%

Analyst Estimates with Stock Price Targets

Financial data from IGM Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	2.68 2.68	27% 27% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	42 42	12% 12% 1,572%
- Research and Development Expense	132 132	37% 37% 4,929%
EBITDA	-162 -162	34% 34% -6,057%
- Depreciation and Amortization	9.21 9.21	5% 5% 344%
EBIT (Operating Income) EBIT	-172 -172	32% 32% -6,401%
Net Profit	-199 -199	16% 16% -7,421%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

IGM Biosciences Inc Stock News

Negative

Market Watch

●

6 months ago

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

Neutral

GlobeNewsWire

●

6 months ago

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

– Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patient...

Company Profile

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firms product pipe line includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies; IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies; and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Head office	United States
CEO	Mary Harler
Employees	149
Founded	2010
Website	igmbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now